Tanke Biosciences Corporation
TNBI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.005 | -0.004 | -0.008 | -0.057 |
| % Growth | -20.5% | 50.6% | 86.1% | – |
| EPS Diluted | -0.005 | -0.004 | -0.008 | -0.057 |
| Weighted Avg Shares Out | 25 | 21 | 12 | 13 |
| Weighted Avg Shares Out Dil | 25 | 21 | 12 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |